Novartis Oncology Head Discusses Cancer Care Challenge With COVID-19
'Unbossed' Culture Helps Tackle Supply Issues
Executive Summary
Susanne Schaffert tells Scrip that policies of prioritizing coronavirus treatment to the detriment of cancer care was a worrying move that is negatively impacting survival and mortality.
You may also be interested in...
Novartis’ Bouchard On Delivering Personalized Cancer Medicine In Asia Pacific, Middle East, Africa
Francis Bouchard, Region Head for AMACO (Asia Pacific, Middle East and Africa Countries), Novartis Oncology, discusses a range of issues around mainstreaming personalized/precision oncology therapies such as Kymriah in the region, including reimbursement systems, partnerships and digital initiatives.
Pandemic Still Putting Pressure On Novartis Oncology Portfolio
As Vas Narasimhan spoke about his worries of missed diagnoses and worse outcomes, Q1 sales at the Swiss major's cancer business remained flat as new patient starts, physician visits and cancer screenings declined due to COVID-19.
Commercial Models Shifting As Pharma Mulls Digital-First Launches
Pharma is assessing digital-first launch strategies amid COVID-19 while a resizing of sales forces and the emergence of "digital orchestrators" may also be in store, the co-founder of healthcare solutions provider Indegene tells Scrip.